Literature DB >> 10960557

Ebselen decreases ozone-induced pulmonary inflammation in rats.

Y Ishii1, K Hashimoto, K Hirano, Y Morishima, M Mochizuki, K Masuyama, A Nomura, T Sakamoto, Y Uchida, M Sagai, K Sekizawa.   

Abstract

We studied the effects of ebselen on rat lung inflammatory responses against ozone exposure. Rats were treated with ebselen every 12 h from 1 h before a single 4-h exposure to 2 ppm ozone. Treatment with ebselen (10 mg/kg) significantly decreased pulmonary inflammation as indicated by the albumin concentration and the number of neutrophils in the bronchoalveolar lavage fluid 18 h after the ozone exposure. Although treatment with ebselen did not alter the macrophage expression of inducible nitric oxide synthase after the ozone exposure, it did markedly inhibit the nitration reaction of tyrosine residues, suggesting that ebselen scavenges peroxynitrite during ozone-induced pulmonary inflammation. Treatment with ebselen also enhanced the pulmonary expression of both copper, zinc, and manganous superoxide dismutases at the same time point. These enzymes may also contribute to a decrease in the formation of peroxynitrite by lowering the concentration of superoxide. Thus, ebselen represents a useful compound for protecting against certain acute lung injuries by modulating the oxidant-related inflammatory process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960557     DOI: 10.1007/s004080000026

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  8 in total

Review 1.  Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways.

Authors:  Gajendra Kumar Azad; Raghuvir S Tomar
Journal:  Mol Biol Rep       Date:  2014-08       Impact factor: 2.316

Review 2.  Glutathione peroxidase-1 as a novel therapeutic target for COPD.

Authors:  Ross Vlahos; Steven Bozinovski
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

3.  Ebselen improves ischemia-reperfusion injury after rat lung transplantation.

Authors:  Jürg Hamacher; Uz Stammberger; Elvira Weber; Rudolf Lucas; Albrecht Wendel
Journal:  Lung       Date:  2009-02-07       Impact factor: 2.584

4.  Topical Therapeutic Efficacy of Ebselen Against Multidrug-Resistant Staphylococcus aureus LT-1 Targeting Thioredoxin Reductase.

Authors:  Chuanjiang Dong; Jingxuan Zhou; Peng Wang; Tao Li; Ying Zhao; Xiaoyuan Ren; Jun Lu; Jun Wang; Arne Holmgren; Lili Zou
Journal:  Front Microbiol       Date:  2020-01-15       Impact factor: 5.640

Review 5.  Therapeutic Potential of Small Molecules Targeting Oxidative Stress in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review.

Authors:  Hamad Ghaleb Dailah
Journal:  Molecules       Date:  2022-08-28       Impact factor: 4.927

6.  Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-throughput screening of existing drugs.

Authors:  Rana Eltahan; Fengguang Guo; Haili Zhang; Lixin Xiang; Guan Zhu
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-01-30       Impact factor: 4.077

Review 7.  Oxidative stress-based therapeutics in COPD.

Authors:  Peter J Barnes
Journal:  Redox Biol       Date:  2020-04-20       Impact factor: 11.799

Review 8.  Antioxidants as Therapeutic Agents in Acute Respiratory Distress Syndrome (ARDS) Treatment-From Mice to Men.

Authors:  Andreas von Knethen; Ulrike Heinicke; Volker Laux; Michael J Parnham; Andrea U Steinbicker; Kai Zacharowski
Journal:  Biomedicines       Date:  2022-01-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.